• Home
  • About Us
  • Blog

Pulmonary Hypertension RN

  • What is Pulmonary Hypertension?
    • What is Pulmonary Hypertension?
    • Pulmonary Hypertension Symptoms
    • Types of Pulmonary Hypertension
    • Causes of Pulmonary Hypertension
    • PH vs. PAH
    • Diastolic Heart Failure vs. PAH
    • WHO Group 3 Pulmonary Hypertension, IPF & COPD
    • Pulmonary Veno-Occlusive Disease
    • Hereditary Hemorrhagic Telangiectasia (HHT)
      • Hereditary Hemorrhagic Telangiectasia (HHT) Treatment
    • Functional Classification of Pulmonary Hypertension
    • Congenital Heart Disease
      • Eisenmenger’s Syndrome
      • Update on Management of PAH-CHD
      • Congenital Heart Disease & Sleep Apnea
      • Complex Congenital Heart Disease
      • Atrial Septal Defect and Pulmonary Arterial Hypertension
    • Pediatric Pulmonary Arterial Hypertension
    • Sickle Cell and Pulmonary Hypertension
    • Stimulant Associated Pulmonary Arterial Hypertension
    • Porto-Pulmonary Syndrome
    • Research, Life Expectancy & Prognosis for PH
  • Diagnosing & Monitoring PAH
    • Pulmonary Arterial Hypertension Diagnosis
    • How Am I Doing? Assessing Your PAH.
    • Blood Tests
    • Cardiopulmonary Exercise Test (CPET)
    • CT (Computed Tomography) Scan
    • Echocardiogram: An Overview
    • Echocardiogram: A Detailed Look
    • Pulmonary Function Tests (PFTs)
    • Right Heart Catheterization
    • Six Minute Walk
    • Ventilation Perfusion Scan (VQ Scan)
    • CTEPH
      • CTEPH: WHO Group 4 Pulmonary Hypertension
      • PTE (Pulmonary Thromboendarterectomy) Surgery
      • Adempas used to Treat PAH and CTEPH
  • PAH Treatment
    • Pulmonary Hypertension Centers
    • Pulmonary Hypertension Treatments
    • Continuously Infused Therapies Used to Treat PH
    • Prostanoids for Treatment of PH
    • Adcirca and Revatio Used to Treat Pulmonary Arterial Hypertension (PAH)
    • Adempas used to Treat PAH and CTEPH
    • Tracleer, Letairis, and Opsumit Treatments
    • Oxygen Therapy for Pulmonary Hypertension
    • Salt and Water Restrictions
    • Exercise & PAH
    • Diuretics
    • Blood Thinners
    • Getting the Most Out of PAH Therapy
      • Letairis
      • Opsumit
      • Sildenafil (Revatio)
  • Research
  • FAQ’s
    • Implanted Remodulin Pump, Right Heart Catheterization, PAH & Pregnancy
    • Oral Treatments, Care Centers & Hole in Heart
    • FAQ’s: Altitude, Cold & Allergy Medications
    • FAQ’s: Psoriasis, Idiopathic PAH, Contraceptives & PAH
    • FAQ’s: Causes of Pulmonary Hypertension, Symptom Frequency & Care Centers
    • FAQ: PAH Experts, Pregnancy, Mild PAH & Vacationing
    • FAQ’s: CTEPH, Blood Clots, Corrective Surgery & PAH Care Centers
    • FAQ’s: VQ Scans & PAH Curable?
    • FAQ’s: Mild Pulmonary Hypertension?
    • FAQ’s: Boating, Swimming & Eating with PAH
    • FAQ’s: Borderline Pulmonary Hypertension, Hand Swelling, Children with PAH, Costs

Porto-Pulmonary Syndrome

October 1, 2020 By Dr. Jeremy Feldman

An important cause of PAH is liver disease.  Up to 5% of patients with cirrhosis (scarring in the liver) or portal hypertension (high pressure in the blood vessels of the liver) can develop PAH.  All causes of cirrhosis and portal hypertension can develop PAH.  

Causes

The most common causes of cirrhosis (scarring of the liver that leads to liver failure) are hepatitis (Hepatitis C in the United States and Hepatitis B in other countries), chronic alcohol abuse and non-alcoholic steatohepatitis (also called fatty liver).  There are many other causes of chronic liver disease including parasitic infections, autoimmune liver disease and rare disorders of metabolism.  Chronic liver disease is often silent until the disease is very advanced.  Most patients have no symptoms until they develop abdominal swelling, leg swelling, abnormal blood tests or jaundice (yellowing of their skin and eyes).  

Liver Transplant

Portopulmonary hypertension

In advanced cirrhosis, liver transplant may be an option but a careful evaluation is required and all patients are evaluated to see if they have PAH.  When present, severe PAH may be a barrier to liver transplantation.  When PAH develops in the context of cirrhosis or portal hypertension, the syndrome is called porto-pulmonary syndrome.  It is important to distinguish which came first.  Long standing PAH can lead to cirrhosis through chronic congestion of the liver. This is not the same as porto-pulmonary syndrome.  

PAH Comes in 2 Types

The PAH of porto-pulmonary syndrome comes in two flavors.  The most common finding is very high blood flow and is associated with mild to moderately elevated pulmonary artery pressure and low pulmonary vascular resistance. This is generally not a barrier to liver transplant as the high blood flows improve after transplantation and the pulmonary pressure normalizes.  

A more worrisome finding is low blood flows and very high pulmonary artery pressure and resistance.  Under these circumstances, liver transplantation may not be an option until the PAH is improved with aggressive therapy.  In previous decades, many liver transplantation programs used a mean (average) pulmonary artery pressure of 35 or more as a contraindication to liver transplantation.  Although some centers still use this number in isolation, other centers take into consideration the blood flow and pulmonary vascular resistance.  

Porto-pulmonary syndrome with high pressures and low blood flows can respond to treatment with the usual PAH medications.  Selecting an optimal regimen depends on the goals of the patient.  If the goal is liver transplantation, then a regimen of two or three medications is often used.  If transplantation is not a goal then the treatments may be less aggressive and titrated to how the patient feels.  

Patients with porto-pulmonary syndrome often have significant fatigue that is driven by their liver failure.  Long term prognosis is guarded in many patients with this disease and is often heavily influenced by their liver disease.   Careful communication between your liver and pulmonary hypertension specialists is critically important.  

Filed Under: Pulmonary Hypertension Diagnosis

PAH Life Expectancy

PAH Research

Research, Life Expectancy & Prognosis for PH

Major Developments in Pulmonary Hypertension Affecting Prognosis 1.     Approval of

Where to Get Treatment?

CCCs for PAH

Pulmonary Hypertension Centers

Where to get treatment for pulmonary hypertension? Pulmonary arterial hypertension is a

Popular Posts

boating with pulmonary arterial hypertension

FAQ’s: Boating, Swimming & Eating with PAH

By Dr. Jeremy Feldman

We greatly appreciate our readers who submit questions.  We try and select questions that are asked by

PAH research

Tyrosine Kinase Inhibition and Pulmonary Arterial Hypertension

By Dr. Jeremy Feldman

30 years ago PAH scientists and doctors believed that PAH was caused by inappropriate or excessive squeezing

good news in pah

 

Disclaimer

Recent Blog Posts

  • In Memoriam:  Greg Ahearn, MD June 16, 2024
  • Sotatercept (Winrevair) Approved! June 1, 2024
  • Disappointing News for Rodatristat Ethyl October 11, 2023

Categories

Archives